CHANDAN
Chandan Healthca financials
- Market cap
- ₹564 Cr
- Sector
- Healthcare
- Calls analysed
- 4
Chandan Healthca Q1 FY27
What went well
- Consolidated sales of ₹82.26 crores, up 19.62% YoY.
- Consolidated EBITDA of ₹20.98 crores, up 42.27% YoY, with margin at 25.51% (up 4.6 bps).
- Standalone diagnostics revenue of ₹49.75 crores, up 35.85% YoY, with EBITDA margin at 36.57% (up 285 bps).
What Chandan Healthca does
Chandan Healthcare operates a network of diagnostic centres, laboratories and sample-collection points across Uttar Pradesh, Uttarakhand and neighbouring states, offering pathology testing (routine, specialised hormone/tumour-marker/genetic panels and preventive health packages) and radiology imaging (X-ray, ultrasound, CT, MRI, PET and mammography). It complements this with a pharmacy arm running company-owned retail outlets selling pharmaceuticals, surgical products and FMCG items, backed by a centralised cold-chain distribution system. The company serves retail walk-in patients (B2C), institutional tie-ups with private hospitals and clinics (B2B), and government public-private-partnership diagnostic contracts (B2G), with all centres company-owned and operated for consistent quality control.
Segments
- Pathology
- Radiology
- Pharmacy
- Diagnostic centres
- 60+
- Geographic presence
- 51 cities across 13 states
- Sample collection centres
- 360
- Team size
- 1,700+
- Total tests conducted (FY26)
- 8.8 million
- Total patient count (FY25)
- 18.21 lakh
Guidance record · Q1 FY27
what the last two calls moved 15 tracked 1 delivered 2 missed 12 open- Pharmacy EBITDA Margin delivered said Q2 FY26 Promised: Over 10% in next 6 months or so Q1 FY27: Company announced the divestment of its entire 53.56% stake in Chandan Pharmacy Limited, strategically exiting the low-margin business to focus on diagnostics. This resolves the issue by eliminating the business unit.
- New Labs Capacity went quiet said Q2 FY26 Promised: 100 labs in next 3 years Q1 FY27: The original target of '100 labs' was not mentioned. It has been superseded by more specific and ambitious targets: 8 comprehensive centers and 6+ diagnostic centers this year, plus a 'One District One Lab' program.
- Franchisee Collection Points revised up said Q2 FY26 Promised: More than 1,000 new franchise collection points Q1 FY27: Due to strong response (102 franchises added in one month), management has drastically accelerated the target to achieve 1,000 franchises within the current financial year (FY27).
All 15 tracked — every revision, and every one management stopped mentioning.
Open the guidance ledgerQuarterly results
Q1 FY27: revenue up 19.1%, net profit up 27.9% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 110 | 55 | 63 | 68 | 68 −38% | 65 +19% | 76 +21% | 81 +19% |
| EBITDA | 20 | 9 | 10 | 14 | 14 −29% | 12 +33% | 11 +12% | 20 +41% |
| Net profit | 11 | 4 | 6 | 6 | 8 −29% | 5 +8% | 5 −18% | 8 +28% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance −12.2% 1Y
1Y: ₹227.5 on 10 Sept 2025 → ₹199.8. High ₹347.2 (19 Nov 2025), low ₹199.8 (11 Sept 2026).
How the price took the results
close before → close after
- Q1 FY27
- −1.8%
- 20 Aug
- Q4 FY26
- −6.0%
- 1 Jun
- Q3 FY26
- −8.0%
- 16 Feb
- Q2 FY26
- +7.6%
- 17 Nov
The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.
Financials, as filed
| Year ending | FY26 |
|---|---|
| Revenue | ₹276 Cr |
| Operating profit | ₹51 Cr |
| Operating margin | 18.6% |
| Interest | ₹6 Cr |
| Depreciation | ₹12 Cr |
| Net profit | ₹23 Cr |
| Net margin | 8.5% |
| Cash from operations | ₹16 Cr |
| Free cash flow | ₹-26 Cr |
| ROCE | 23.0% |
How to read this
From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.
Balance sheet
| Year ending | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Equity capital | ₹20 Cr | ₹20 Cr | ₹20 Cr | ₹24 Cr | ₹24 Cr |
| Reserves | ₹4 Cr | ₹7 Cr | ₹21 Cr | ₹114 Cr | ₹147 Cr |
| Borrowings | ₹17 Cr | ₹21 Cr | ₹36 Cr | ₹67 Cr | ₹54 Cr |
| Other liabilities | ₹41 Cr | ₹49 Cr | ₹41 Cr | ₹68 Cr | ₹65 Cr |
| Total liabilities | ₹82 Cr | ₹98 Cr | ₹118 Cr | ₹273 Cr | ₹290 Cr |
| Fixed assets | ₹29 Cr | ₹33 Cr | ₹48 Cr | ₹91 Cr | ₹101 Cr |
| Capital work in progress | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹5 Cr | ₹12 Cr |
| Investments | ₹6 Cr | ₹7 Cr | ₹3 Cr | ₹47 Cr | ₹20 Cr |
| Other assets | ₹46 Cr | ₹58 Cr | ₹66 Cr | ₹130 Cr | ₹156 Cr |
| Total assets | ₹82 Cr | ₹98 Cr | ₹118 Cr | ₹273 Cr | ₹290 Cr |
How to read this
As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Who owns it
As disclosed at Jun 2026
Since Mar 2025, the public added +4.91 pp while FIIs trimmed −3.85 pp. The shareholder count grew 77% to 1,591.
- Promoters
- 49.6%
- FIIs
- 0.0%
- DIIs
- 5.1%
- Public
- 45.3%
Since Mar 2025
- Public +4.91 pp
- FIIs −3.85 pp
- DIIs −1.23 pp
How it drifted, 5 quarters
Over this window the public went from 40.4% to 45.3% — +4.9 pp.
Ownership split by quarter, oldest first. Mar '25: Promoters 49.4%, FIIs 3.9%, DIIs 6.3%, Public 40.4%.Sep '25: Promoters 49.5%, FIIs 1.1%, DIIs 5.0%, Public 44.4%.Dec '25: Promoters 49.5%, DIIs 4.8%, Public 45.8%.Mar '26: Promoters 49.5%, FIIs 0.0%, DIIs 5.0%, Public 45.4%.Jun '26: Promoters 49.6%, FIIs 0.0%, DIIs 5.1%, Public 45.3%.
Who bought this quarter
since Mar 2026
Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.
- Amaranita Holdings (India) Private Limited +0.12 pp 17.00% held
- CHANDAN CRADLE LIMITED (Formerly Known as CHANDAN FERTILITY LIMITED ) newly disclosed 0.00% held
The same filing shows 1 holder trimming and 0 off the list — both are in the register beside this.
Who is on the register
Named in the Jun 2026 filing
Every holder of Chandan Healthca above SEBI's 1% disclosure line, and what changed since Mar 2026.
| Holder | Stake | Change |
|---|---|---|
| Amaranita Holdings (India) Private Limited | 17.00% | +0.12 pp |
| Amar Singh | 9.61% | unchanged |
| Vinay Lamba | 6.48% | unchanged |
| Shaleen Solanki | 3.68% | unchanged |
| Vijay Singh | 3.68% | unchanged |
| Negen Undiscovered Value Fund AIF | 3.16% | unchanged |
| Vikas Lamba | 1.84% | unchanged |
| Shweta Lamba | 1.72% | unchanged |
| Anant Wealth Consultants | 1.63% | unchanged |
| Hari Shanker Dixit | 1.43% | unchanged |
| Shalu Aggarwal | 1.42% | unchanged |
| Amit Srivastava | 1.40% | unchanged |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
What the price assumes
- Growth the price implies
- 12.1% a year
- for 7 years, fading to 4%
- It has actually compounded at
- Not enough history
- The gap
- —
- between what it did and what it must do
All earnings calls (4)
Read the Q1 FY27 call →Learn to analyse Chandan Healthca
Guides on how to read this kind of business and the numbers that matter.